Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

The analysis, conducted by Ernst & Young, found the United States imported $203 billion in pharmaceutical products in 2023 ...

Luxembourg-based steelmaker ArcelorMittal is bringing on lobbying firepower as the steel conglomerate seeks to defend its ...

CNBC's Jim Cramer on Friday walked investors through another busy week in the thick of earnings season, pointing out reports ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Mining and transport conglomerate Grupo Mexico reported a 17% jump in first-quarter net profit on Friday, primarily driven by ...

DoorDash has asked a California Superior Court judge to dismiss a lawsuit filed by Uber that accuses the food delivery ...

Owned by Vietnam’s wealthiest man, VinFast is more immune to not making a profit. On Thursday, the company reported it lost ...